The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Phase II Study of Autologous Monocyte-Derived mRNA Electroporated Dendritic Cells (TriMixDC-MEL) Plus Ipilimumab in Patients With Pretreated Advanced Melanoma
Abstract
Purpose: Autologous monocyte-derived dendritic cells (DCs) electroporated with synthetic mRNA (TriMixDC-MEL) are immunogenic and have antitumor activity as a monotherapy in patients with pretreated advanced melanoma. Ipilimumab, an immunoglobulin G1 monoclonal antibody directed against the cytotoxic T-lymphocyte-associated protein 4 receptor that counteracts physiologic suppression of T-cell function, improves the overall survival of patients with advanced melanoma. This phase II study investigated the combination of TriMixDC-MEL and ipilimumab in patients with pretreated advanced melanoma. Patients and Methods: Thirty-nine patients were treated with TriMixDC-MEL (4 × 10 6 cells administered intradermally and 20 × 10 6 cells administered intravenously) plus ipilimumab (10 mg/kg every 3 weeks for a total of four administrations, followed by maintenance therapy every 12 weeks in patients who remained progression free). Six-month disease control rate according to the immune-related response criteria served as the primary end point. Results: The 6-month disease control rate was 51% (95% CI, 36% to 67%), and the overall tumor response rate was 38% (including eight complete and seven partial responses). Seven complete responses and one partial tumor response are ongoing after a median follow-up time of 36 months (range, 22 to 43 months). The most common treatment-related adverse events (all grades) consisted of local DC injection site skin reactions (100%), transient post–DC infusion chills (38%) and flu-like symptoms (84%), dermatitis (64%), hepatitis (13%), hypophysitis (15%), and diarrhea/colitis (15%). Grade 3 or 4 immune-related adverse events occurred in 36% of patients. There was no grade 5 adverse event. Conclusion: The combination of TriMixDC-MEL and ipilimumab is tolerable and results in an encouraging rate of highly durable tumor responses in patients with pretreated advanced melanoma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496
Optimal two-stage designs for phase II clinical trials.
Simon, R. (1989) · Controlled Clinical Trials · doi:10.1016/0197-2456(89)90015-9 · Cited by 3,636
Wolchok, J. D., Hoos, A., O'Day, S., Weber, J. S., Hamid, O., Lebbé, C., Maio, M., Binder, M., Bohnsack, O., Nichol, G., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1624 · Cited by 3,222
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma
Postow, M. A., Chesney, J., Pavlick, A. C., Robert, C., Grossmann, K., McDermott, D., Linette, G. P., Meyer, N., Giguere, J. K., Agarwala, S. S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414428 · Cited by 2,781
Immune Checkpoint Blockade in Cancer Therapy
Postow, M. A., Callahan, M. K., & Wolchok, J. D. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.4358 · Cited by 2,709
CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation.
Krummel, M. F., & Allison, J. P. (1995) · The Journal of experimental medicine · doi:10.1084/jem.182.2.459 · Cited by 2,245
Schadendorf, D., Hodi, F. S., Robert, C., Weber, J. S., Margolin, K., Hamid, O., Patt, D., Chen, T.-T., Berman, D. M., & Wolchok, J. D. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.2736 · Cited by 2,141 · cited 1×
“The 2- and 3-year survival rates compare favorably with the long-term outcomes of prospective clinical trials of ipilimumab monotherapy in patients with pretreated advanced melanoma.(6,7,10) In accordance with previous observations, a correlation was found between an increase in eosinophil counts and survival, but not…”
ResultTrans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4
Qureshi, O. S., Zheng, Y., Nakamura, K., Attridge, K., Manzotti, C., Schmidt, E. M., Baker, J., Jeffery, L. E., Kaur, S., Briggs, Z., et al. (2011) · Science · doi:10.1126/science.1202947 · Cited by 1,860
Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab
Weber, J. S., Kähler, K. C., & Hauschild, A. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.41.6750 · Cited by 1,415 · cited 1×
“All immune-related AEs were managed using established treatment algorithms.(25) Grade 1 to 2 dermatitis (diffuse itching, erythema) was the most frequent AE and was reported by 64% of patients.”
MethodEggermont, A. M. M., Chiarion-Sileni, V., Grob, J.-J., Dummer, R., Wolchok, J. D., Schmidt, H., Hamid, O., Robert, C., Ascierto, P. A., Richards, J. M., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70122-1 · Cited by 1,262
Wolchok, J. D., Neyns, B., Linette, G., Negrier, S., Lutzky, J., Thomas, L., Waterfield, W., Schadendorf, D., Smylie, M., Guthrie, T., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70334-1 · Cited by 1,195
Self-citationvan Elsas, A., Hurwitz, A. A., & Allison, J. P. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.190.3.355 · Cited by 1,020
Krummel, M. F., & Allison, J. P. (1996) · The Journal of experimental medicine · doi:10.1084/jem.183.6.2533 · Cited by 932
Dendritic-Cell-Based Therapeutic Cancer Vaccines
Palucka, K., & Banchereau, J. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.004 · Cited by 869
Ribas, A., Kefford, R., Marshall, M. A., Punt, C. J. A., Haanen, J. B., Marmol, M., Garbe, C., Gogas, H., Schachter, J., Linette, G., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.6112 · Cited by 805
O'Day, S. J., Maio, M., Chiarion-Sileni, V., Gajewski, T. F., Pehamberger, H., Bondarenko, I. N., Queirolo, P., Lundgren, L., Mikhailov, S., Roman, L., et al. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq013 · Cited by 514
Ku, G. Y., Yuan, J., Page, D. B., Schroeder, S. E. A., Panageas, K. S., Carvajal, R. D., Chapman, P. B., Schwartz, G. K., Allison, J. P., & Wolchok, J. D. (2010) · Cancer · doi:10.1002/cncr.24951 · Cited by 422
Anti–CTLA-4 therapy broadens the melanoma-reactive CD8 + T cell response
Kvistborg, P., Philips, D., Kelderman, S., Hageman, L., Ottensmeier, C., Joseph-Pietras, D., Welters, M. J. P., van der Burg, S., Kapiteijn, E., Michielin, O., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008918 · Cited by 378
Self-citationYuan, J., Gnjatic, S., Li, H., Powel, S., Gallardo, H. F., Ritter, E., Ku, G. Y., Jungbluth, A. A., Segal, N. H., Rasalan, T. S., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0810114105 · Cited by 348
Delyon, J., Mateus, C., Lefeuvre, D., Lanoy, E., Zitvogel, L., Chaput, N., Roy, S., Eggermont, A. M. M., Routier, E., & Robert, C. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt027 · Cited by 318
Dendritic Cell Vaccination Combined with CTLA4 Blockade in Patients with Metastatic Melanoma
Ribas, A., Comin-Anduix, B., Chmielowski, B., Jalil, J., de la Rocha, P., McCannel, T. A., Ochoa, M. T., Seja, E., Villanueva, A., Oseguera, D. K., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1254 · Cited by 217
Wilgenhof, S., Van Nuffel, A. M. T., Benteyn, D., Corthals, J., Aerts, C., Heirman, C., Van Riet, I., Bonehill, A., Thielemans, K., & Neyns, B. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt245 · Cited by 203
Self-citationBonehill, A., Tuyaerts, S., Van Nuffel, A. M., Heirman, C., Bos, T. J., Fostier, K., Neyns, B., & Thielemans, K. (2008) · Molecular Therapy · doi:10.1038/mt.2008.77 · Cited by 185
Self-citationPulmonary Sarcoid-Like Granulomatosis Induced by Ipilimumab
Berthod, G., Lazor, R., Letovanec, I., Romano, E., Noirez, L., Mazza Stalder, J., Speiser, D. E., Peters, S., & Michielin, O. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.3298 · Cited by 182
Bonehill, A., Van Nuffel, A. M. T., Corthals, J., Tuyaerts, S., Heirman, C., François, V., Colau, D., van der Bruggen, P., Neyns, B., & Thielemans, K. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2982 · Cited by 167
Self-citationHannani, D., Vétizou, M., Enot, D., Rusakiewicz, S., Chaput, N., Klatzmann, D., Desbois, M., Jacquelot, N., Vimond, N., Chouaib, S., et al. (2015) · Cell Research · doi:10.1038/cr.2015.3 · Cited by 162
Wilgenhof, S., Van Nuffel, A. M. T., Corthals, J., Heirman, C., Tuyaerts, S., Benteyn, D., De Coninck, A., Van Riet, I., Verfaillie, G., Vandeloo, J., et al. (2011) · Journal of Immunotherapy · doi:10.1097/cji.0b013e31821dcb31 · Cited by 159
Self-citationAnti-CTLA4 Monoclonal Antibody Induced Sarcoidosis in a Metastatic Melanoma Patient
Eckert, A., Schoeffler, A., Dalle, S., Phan, A., Kiakouama, L., & Thomas, L. (2008) · Dermatology · doi:10.1159/000161122 · Cited by 138
Hannani, D., Vétizou, M., Enot, D. P., Rusakiewicz, S., Chaput, N., Klatzmann, D., Desbois, M., Jacquelot, N., Vimond, N., Chouaïb, S., et al. (2015) · Cell Research · doi:10.1038/cr.2015.28 · Cited by 135
Ipilimumab-Induced Sarcoidosis in a Patient With Metastatic Melanoma Undergoing Complete Remission
Vogel, W. V., Guislain, A., Kvistborg, P., Schumacher, T. N., Haanen, J. B. A. G., & Blank, C. U. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.37.9693 · Cited by 127
Self-citationMurphy, K. P., Kennedy, M. P., Barry, J. E., O'Regan, K. N., & Power, D. G. (2014) · Oncology Research and Treatment · doi:10.1159/000362614 · Cited by 88
Van Nuffel, A. M., Benteyn, D., Wilgenhof, S., Pierret, L., Corthals, J., Heirman, C., van der Bruggen, P., Coulie, P. G., Neyns, B., Thielemans, K., et al. (2012) · Molecular Therapy · doi:10.1038/mt.2012.11 · Cited by 86
Self-citationWilgenhof, S., Morlion, V., Seghers, A. C., Four, S. D., Vanderlinden, E., Hanon, S., Vandenbroucke, F., Everaert, H., & Neyns, B. (2012) · PubMed · Cited by 82
Self-citationCutaneous and pulmonary sarcoidosis-like reaction associated with ipilimumab
Reule, R. B., & North, J. P. (2013) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2013.07.028 · Cited by 79
de Vries, I. J. M., Castelli, C., Huygens, C., Jacobs, J. F. M., Stockis, J., Schuler‐Thurner, B., Adema, G. J., Punt, C. J. A., Rivoltini, L., Schuler, G., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2227 · Cited by 78
Self-citationAndersen, R. S., Nørgaard, P. H., Al-Jailawi, M. K. M., & Svane, I. M. (2014) · OncoImmunology · doi:10.4161/21624011.2014.954506 · Cited by 62
Tissot, C., Carsin, A., Freymond, N., Pachéco, Y., & Devouassoux, G. (2012) · European Respiratory Journal · doi:10.1183/09031936.00107912 · Cited by 60
Lutzky, J., Wolchok, J., Hamid, O., Lebbe, C., Pehamberger, H., Linette, G., de Pril, V., Ibrahim, R., Hoos, A., & O'Day, S. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.9034 · Cited by 58 · cited 1×
“Such correlation has been reported previously for ipilimumab monotherapy but did not reach significance.(42) Resembling previous observations on patients treated with corticosteroids to control immune-related AEs related to ipilimumab, we suspect no detrimental effect from our observations.”
ResultMet, Ö., Wang, M., Pedersen, A. E., Nissen, M. H., Buus, S., & Claësson, M. H. (2005) · Cancer Letters · doi:10.1016/j.canlet.2005.02.005 · Cited by 51
Marlier, J., Cocquyt, V., Brochez, L., Belle, S. V., & Krüse, V. (2014) · Endocrine · doi:10.1007/s12020-014-0199-9 · Cited by 41
Amin, A., DePril, V., Hamid, O., Wolchock, J. D., Maio, M., Neyns, B., Chin, K. M., Ibrahim, R. A., Hoos, A., & O'Day, S. J. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.9037 · Cited by 38
Self-citationKrummel, M. F., & Allison, J. P. (2011) · The Journal of Immunology · doi:10.1093/ji/187.7.3459 · Cited by 36
Cited by
mRNA vaccines — a new era in vaccinology
Pardi, N., Hogan, M. J., Porter, F. W., & Weissman, D. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.243 · Cited by 4,667
Roles of the immune system in cancer: From tumor initiation to metastatic progression
Gonzalez, H., Hagerling, C., & Werb, Z. (2018) · Genes & Development · doi:10.1101/gad.314617.118 · Cited by 2,111
Saxena, M., van der Burg, S. H., Melief, C. J. M., & Bhardwaj, N. (2021) · Nature reviews. Cancer · doi:10.1038/s41568-021-00346-0 · Cited by 1,581
Melief, C. J. M., van Hall, T., Arens, R., Ossendorp, F., & van der Burg, S. H. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80009 · Cited by 1,164
Dendritic cell-based immunotherapy
Sabado, R. L., Balan, S., & Bhardwaj, N. (2017) · Cell Research · doi:10.1038/cr.2016.157 · Cited by 927
Metadata
- Authors
- Wilgenhof, S., Corthals, J., Heirman, C., van Baren, N., Lucas, S., Kvistborg, P., Thielemans, K., & Neyns, B.
- Venue
- Journal of Clinical Oncology
- Published
- 2016-04-20
- Volume
- 34
- Issue
- 12
- Pages
- 1330-1338
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2291366206
- Cited by
- 313
- References
- 45
- FWCI
- 16.32
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.